Search - tctmd.com

Displaying 1 - 5 of 5

Sort: Relevancy | Date

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

News Industry News

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

April 26, 2018

News Industry News

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

January 24, 2016

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.